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Abstract
Diagnosis of autoimmune diseases is crucial for the clinician and the patient 
alike. The immunoassay techniques most commonly used for this purpose are 
immunohistochemistry, ELISA, and Western blotting. For the detection of more 
specific biomarkers or the discovery of new ones for diagnostic purposes and as 
therapeutic targets, microarray techniques are increasingly used, for example, 
protein microarray, Luminex, and in recent years, surface plasmon resonance 
imaging. All of these technologies have undergone changes over time, making them 
easier to use. Similar technologies have been invented but responding to specific 
requirements for both diagnostic and research purposes. The goals are to study 
more analytes in the same sample, in a shorter time, and with increased accuracy. 
The reproducibility and reliability of the results are also a target pursued by manu-
facturers. In this chapter, we present these technologies and their utility in the 
diagnosis of immunogenetic diseases.
Keywords: immunoassay, protein biomarkers, autoimmune diseases, IHC,  
ELISA, WB, protein microarray, SPRi, Luminex
1. Introduction
An autoimmune pathology occurs when the immune system loses its ability to 
distinguish between its own cells and nonself cells, inducing the attack of self-
tissue. This mechanism involves both the environmental factors and the genetic 
predisposition of the individual.
Proteomic technologies identify and separate different proteins of interest from 
biological samples, thus enabling their characterization as biomarkers, establishing 
their interactions, their role and the mechanisms in which they are involved, the 
identification of new diagnostic and therapeutic targets. The identification of pro-
tein biomarkers may be the basis for developing new methods of early diagnosis and 
treatment [1]. In general, an ideal biomarker should meet certain characteristics: be 
specific to a particular disease, be validated and confirmed as having specificity for 
that pathology, be able to early identify the disease, its testing to be easy and cheap 
as far as possible, reliable, and noninvasive [2, 3].
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Although important advances have been made in deciphering immune func-
tion, the understanding of this function dysregulation and the specific autoim-
mune response remains limited. The domain is complex and includes, besides 
the disturbance of immune system functioning, gene alterations that regulate 
and control the self-tolerance. In this chapter, we will describe the techniques of 
highlighting the proteomic biomarkers involved in the pathogenesis of immuno-
genetic diseases.
In the case of immunogenetic diseases, one of the tissues that are first tested 
for specific biomarkers is blood, namely, the serum, which contains approximately 
60–80 mg/mL proteins, besides amino acids, lipids, salts, and carbohydrates [4]. 
Applying proteomic immunoassay techniques for the diagnosis of immunogenetic 
diseases may also predict the course of disease, or result in a personalized treatment 
for patients [5, 6].
Proteomic biomarkers are particularly useful for providing the information on cel-
lular signaling pathways, bringing early disease data, monitoring treatment response 
or adverse effects. They can be monitored from body fluids other than blood, such as: 
urine, saliva, cerebrospinal fluid and from different tissues (biopsies) [7].
The necessity to analyze very small amounts of proteins present in biological 
samples [8], as well as the increase in the number of proteins requiring simultane-
ous, reliable, reproducible, and significant investigations led to the moderniza-
tion of the existing techniques and to the appearance of some new methods of 
biomarker investigation and analysis. Immunohistochemistry, ELISA, and Western 
blotting are of the old methods that changed, adapted, modernized over time, but 
remained “on barricades” for protein biomarker investigation, especially in autoim-
mune disorders. Immunoassay methodologies are the most commonly used tools 
in protein research, using the properties of antibodies to bind different protein 
domains and to mark them. Next, the methods abovementioned are the other high 
sensitivity technics for validating proteomic biomarkers such as protein microarray, 
surface plasmon resonance, and Luminex multiplex assays. In recent years, many 
multiplexed immunodetection techniques have been developed to simultaneously 
investigate multiple proteins (from several tens to several hundreds), in the same 
sample, and which are in very low amounts (Figure 1).
Figure 1. 
The schematic representation of the immunoassay methods presented in this chapter, more or less in the order 
in which they appeared in time and how they evolved. These methods are based on the protein/antigen-
antibody reaction that is shown on the left side—here is the indirect method: antigen → primary antibody → 
secondary antibody conjugated with a fluorochrome or an enzyme.
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In many cases, the immunoassay techniques are used in conjunction for diagnos-
tic, to confirm the presence of autoantibodies and then to characterize the expres-
sion of one or more specific biomarkers for a certain disease. More of this, these 
techniques can validate their mutual results.
2. Immunohistochemistry
The technique of immunohistochemistry (IHC) is a basic one, both in the 
anatomopathological diagnosis and in the research. It allows viewing of a pro-
tein of interest in a tissue section, specifying its location. This last aspect is very 
important and distinct IHC from other immunodetection techniques. The pres-
ence, reduction or the absence of the target protein allows a precise diagnosis 
or a personalized one. We do not intend to describe the technique itself, but we 
would like to mention it as the method of identifying immune antigens of interest, 
including immunogenetic diseases.
Based on the principle of the antigen-antibody reaction, this technique has 
undergone improvements over time. It started with a direct IHC method, the reac-
tion antigen (target protein)-antibody, coupled with a fluorochrome. The first data 
on an attempt to use the direct IHC are from 1934 [9], but the use of fluorochrome 
for the first time was described in 1941 [10]. The introduction of an enzyme con-
jugated with an antibody and the visualization of the protein in light microscopy is 
due to Nakane and Pierce team [11]. The disadvantage of the IHC direct method is 
its low sensitivity.
Afterwards, an IHC indirect method was developed as follows: antigen-primary 
antibody, nonconjugated-secondary antibody (anti-primary antibody), conjugated 
with a fluorochrome or an enzyme, which convert a soluble substrate into an 
insoluble colored substrate [12, 13]. This method allowed the visual signal to be 
intensified.
The need to improve more the signal amplification has led to new changes. Thus 
the secondary antibody has been conjugated with other substances, such as biotin 
molecules, which in turn form complexes with streptavidin, forming a complex 
with an enzyme (e.g., horseradish peroxidase) [14]. More recently, an even more 
sensitive method was used in which a large number of secondary antibodies and 
enzymes are conjugated to a polymer chain (e.g., dextran) [15].
In the IHC technique, even an array-like reaction can be carried out on the same 
tissue section by targeting several proteins by using antibodies from different spe-
cies (mouse, rabbit, goat, etc.), different enzymes coupled to the secondary anti-
body (e.g., horseradish peroxidase and alkaline phosphatase), different chromogens 
(e.g., 3,3′diaminobenzidine or 5-bromo-4-chloro-3-indolyl phosphate/nitro blue 
tetrazolium) or fluorochromes (e.g., FITC and rhodamine) with different colors.
Sometimes, especially when the protein of interest is low and the immunohisto-
chemical signal is weak or with interruptions, a confirmation for protein expression 
by Western blotting is required. This confirmation is also required when we are not 
sure whether the antibody specifically binds to the protein of interest or if there is a 
nonspecific antibody labeling. The Western blot technique allows the identification 
of the protein as it is shown below.
3. Enzyme-linked immunosorbent assay (ELISA)
Old traditional ELISA technique was developed in 1971 by Engvall and Perlmann 
[16] and Van Weemen and Schuurs [17] and continues to be nowadays widely used 
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as a routine diagnostic method allowing quantitation of a large variety of proteins 
[18]. The single-plex ELISA, the most utilized assay method performed in 96- or 
384-well plates, has played a prominent role in the quantitative and qualitative 
identification of analytes.
Direct ELISA, the simplest type of ELISA, could accurately quantify a specific 
molecule with high sensitivity from a wide variety of samples, and it is faster [19]. 
But the signal is less amplified.
Indirect ELISA detection is a two-step ELISA which involves a primary antibody 
and a labeled secondary antibody [20]. This method presents a higher sensitivity and 
flexibility (different primary detection antibodies can be used with a single labeled 
secondary antibody). The disadvantage is the occurrence of nonspecific signals.
Beside direct and indirect detection models, two other ELISA methods 
appeared, to avoid false positive or false negative results, with a high specificity, 
suitable for complex samples, with more sensitivity and flexibility: sandwich ELISA 
(quantify antigens between the two layers of antibodies) [21] and competitive ELISA 
(based on a competitive binding process between the original antigen in the sample 
and the add-in antigen, the more antigen in the sample, the less labeled antigen is 
retained in the well and the weaker the signal) [22].
Another ELISA method is ELISpot assay, widely used to evaluate an immune 
response, for example, in allergies or in autoimmunity [23, 24]. This technique, 
performed on PVDF membranes, has advantages like specificity, sensitivity, and 
wide range of detection.
However, the use of ELISA for assessing multiple analytes might be time con-
suming due to the large number of workflows occurring simultaneously. Moreover, 
ELISA is designed as a solid-state immunoassay, and the use of a planar matrix can 
restrict immunoassay capacity, sensitivity, and detection quality [25].
Conventional single-target assays ELISA and Western blot are suitable for bio-
marker validation, but could be expensive, time consuming, and sample limiting. 
While most of the disease conditions may arise when only one single molecule is 
altered, more often it is the consequence of the interaction between several mol-
ecules within the inflammation milieu; therefore, studying the diseases necessitates 
a comprehensive perspective.
ELISA on a chip. In order to improve the method, in terms of using smaller quan-
tities of samples, shortening the reaction time, avoiding sophisticated reading equip-
ment, and reducing costs, a group of researchers tried to miniaturize the ELIZA 
platform [26]. They developed an ELIZA lab-on-a-chip system (ELIZA-LOC), which 
allows the use of only 5 μl of sample on a miniaturized 96-well plate combined with a 
CCD camera [27]. This system combines three functional elements: (i) reagent load-
ing fluidics, (ii) assay and detection well plate, and (iii) reagent removal fluidics. 
The description of LOM technology (laminated object manufacturing) to obtain this 
system using polymer sheets was made by Rasooly et al. [28].
Besides miniaturization, another novelty is the washing step that is integrated 
directly in ELISA plate. The authors state that using this technology, there is no 
need for a specialized laboratory to perform the ELIZA test.
4. Western blot
The Western blot (WB), also known as immunoblot, is an analytical and 
quantitative technique for identifying specific proteins in many biological samples, 
liquid or tissue/cellular homogenates [29]. The WB technique brings concrete 
and useful information that cannot be offered by other immunoassay methods. If 
the target protein, present in the sample, is altered qualitatively or quantitatively, 
5Immunoassay Techniques Highlighting Biomarkers in Immunogenetic Diseases
DOI: http://dx.doi.org/10.5772/intechopen.75951
the band thickness is changed compared to a control being downregulated or 
overexpressed. The WB results can also guide us to a genetic investigation in case 
of partial deletion or duplication in the protein gene [30]. In addition, the WB 
method allows a quick comparison of target protein expression in many patients in 
medical diagnosis.
The WB technique was invented by Harry Towbin and co-workers in 1979. They 
used the method to identify bacterial or chicken ribosomal proteins separated on 
polyacrylamide gels containing urea. They called this method “electrophoretic blot-
ting technique” [31]. The WB name was given 2 years later by Neal Burnette, which 
also brought some improvements to this method, including the use of SDS-PAGE 
gels [32]. The name “Western” was inspired by the earlier name of other blotting 
methods, “Southern”, named after the name of Edwin Southern, who published in 
1975 a method for detecting specific DNA sequences [33], and “Northern” whose 
name was inspired by the name of the first blotting technique, “Southern”, a RNA 
detection technique, developed in 1977 by Alwine et al. [34].
Over time, the method has improved and has become easier to achieve, with 
nearly all materials commercially available: transfer devices, antibodies, pre-casting 
gels, digital imaging devices, and so on. However, in the most part, as methodology, 
the technique proposed by the Towbin team remains valid after 38 years. Burnette, 
Stark, and Towbin said after many years that they were surprised by the success and 
longevity of the method [35].
In summary, the Western blot method is a way to identify a target protein from a 
biological sample, a mixture of proteins, running it on polyacrylamide gel. The pro-
teins in the sample are separated by SDS-PAGE gel electrophoresis, depending on 
their molecular weight. Because the gel is hard to handle, being fragile, the proteins 
are transferred to a membrane, usually nitrocellulose or PVDF (polyvinylidene 
fluoride), that maintains the gel pattern as a copy [7]. The electrical current causes 
the transfer. For visualization of the protein of interest, the membrane is probed 
by a specific primary antibody, it binds the specific epitope of the protein, and it 
is labeled by addition of a secondary antibody recognizing the primary antibody 
conjugated with a detection reagent (fluorophore, enzyme, and radioisotope). The 
visualization is done colorimetric, by chemiluminescence, on X-ray film, or directly 
in the membrane with the aid of an imaging system.
In order to be able to reuse a WB membrane that has already been exposed to 
primary and secondary antibodies, it is necessary to wash it. This operation is called 
stripping. Only membranes that have been treated with ECL (enhanced chemi-
luminescence kit) for protein visualization by chemiluminescence can be reused. 
This method is useful when we want to investigate more proteins on the same blot, 
for example, a protein of interest and a loading control protein. It saves biological 
samples, time, and substances. For stripping, special buffers are using that can 
efficiently remove antibodies but do not remove too much amount of the proteins 
on the membrane.
The WB system size may vary, with electrophoresis/transfer tank, gels, and 
membrane: mini, midi, and large, depending on the investigated protein size and 
the time needed for separation. However, the vast majority of investigators use now 
the mini system, sometimes the midi one, because of the existence of gradient gels 
and more sophisticated devices (see below). Transfer systems were developed by 
few companies to allow proteins the migration from gel to the membrane in dif-
ferent ways, using varying amounts of buffers: wet, semidry, or dry systems. New 
digital technologies offer a good and rapid bands visualization, avoiding underex-
posure or overexposure, as in the case of X-ray film developing. The images can be 
stored in a computer database and can be analyzed with software that measures the 
optical density of the bands.
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4.1 Other methods based on the Western blotting technique
4.1.1 Multiplex Western blot
In the last few years, it has become a necessity to analyze multiple target proteins 
at the same time, in order to compare the expression of proteins involved in a spe-
cific pathology. First Multiplex WB experiment (multiplex Western blot (MWB)) 
was optimized by Anderson and Davison [36] to study different muscle proteins 
involved in muscular dystrophies. This method allowed a simultaneously screen-
ing of multiple proteins with a different size on a pair of blots, using a cocktail of 
monoclonal antibodies which permitted the identification of primary deficient and 
second deficient proteins in several muscle pathologies, knowing that the primary 
reduction of a protein causes the secondary reduction of another protein. The use 
of a MWB allowed establishing a biomarker profile for each patient, providing 
valuable information for diagnosis as well as for phenotype-genotype correlations. 
The MWB method proposed by Anderson used a biphasic polyacrylamide gel (with 
different concentrations) system electrophoresis, which separated the proteins with 
different molecular weights: molecular mass more than 200 kDa in the upper part 
of the gel, with 5.5–4% polyacrylamide gradient, while proteins with molecular 
mass under 150 kDa are separated in the lower phase, 7% polyacrylamide gel.
Introduction of this technique has revolutionized the medical diagnosis and 
opened new perspectives in biomedical research. Simultaneous analysis of several 
proteins involved in different pathologies by MWB reduced the cost and time for 
analysis. By this method, it could be determined and compared proteins in the same 
sample as well as a secondary reduction of other proteins in a specific disease [37, 38].
4.1.2 Capillary electrophoresis and capillary Western blotting
By this method, the molecules are separated by the size inside a capillary filled 
with an electrolyte. The advantage of the method is that the separating sieve matrix 
can be automatically pumped in and out because it contains rather unknown 
polymers than the typical cross-linked polymers for the gels. The big difference 
between the classical method and this one is that many samples can be run over and 
over again in an automated manner that saves a lot of time [35].
Capillary electrophoresis (CE) needs a smaller amount of sample than SDS-
PAGE and offers a better resolution of a protein size. Proteins travel down the 
capillaries and are spaced according to the size. When the individual proteins 
reach the end of the capillary, they drop on a blotting membrane that moves along 
the capillary opening. It has been shown that classical protein standards such as 
carbonic anhydrase and lysozyme can be separated within an hour using only a few 
nanoliters of the sample [39].
O’Neill et al. [40] have been able to capture the resolved proteins on the capillary 
wall by photochemically activated molecules. This method allowed immune complexes 
to be formed after electrophoresis, in the capillary. Chemiluminescence reagents 
flowed through the capillary, and the image was taken with a CCD camera [40].
4.1.3 Microfluidic Western blotting
This technology reduces much more the amount of the sample required for 
WB and also the length of the capillaries from centimeters to microns, using 
microfluidic channels. He and Herr, in 2009, developed an automated immunob-
lotting method using a single streamlined microfluidic assay. A glass microflu-
idic chip, which has integrated a PAGE electrophoresis with subsequent in situ 
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immunoblotting, allowed a rapid protein separation, directed electrophoretic 
transfer of resolved proteins to an in-line blotting membrane, and a high-efficiency 
identification of proteins of interest using antibody-functionalized membranes  
[41, 42]. The system requires only 0.01–0.5 μg of protein.
4.1.4 Dot blot
It is a method very similar to WB, but the proteins are not separated by gel elec-
trophoresis. The samples are applied in small dots directly on the membrane and 
then spotted through circular templates. After membrane drying, the antibodies are 
applied. The visualization of target protein is made like at WB, chemiluminescent 
or colorimetric. Dot blot is used to test the specificity of some antibodies, to test the 
antibody concentration used for WB, or to evaluate the presence of a target protein 
in the sample before WB.
4.1.5 Far-Western blotting
It is used to detect a protein-protein interaction in vitro. Instead of the primary 
antibody for detecting the protein of interest, this method uses a nonantibody 
protein that binds to the protein of interest. Far-Western blotting detects proteins 
on the basis of the presence or the absence of binding sites for the protein probe. 
This method is important in characterization of protein interactions in biological 
processes such as signal transductions [43], receptor-ligand interactions, or screen 
libraries for interacting proteins.
5. Protein microarray
Protein microarray analysis has an increasingly use both for research purposes as 
well as for various biomedical applications, including the niches ones like evaluating 
markers of apoptosis activated by various therapies such as photodynamic therapy 
(PDT), assessment of epigenetic milieu, or transcriptional activity in treated cells 
[44]. Thus, protein microarray is a proteomic tool that can deliver high-throughput 
data for revealing new therapeutic targets [45].
Protein microarray history has spanned the last two decades, the basic principle 
being identical with ELISA, but there are several advantages such as spotting 
in terms of miniaturization, multiplexing, and large data obtained in an ELISA 
equivalent time. Briefly, biological samples of interest (e.g., serum, plasma, etc.) are 
incubated on a slide containing immobilized antibodies, proteins, or peptides. An 
antigen-antibody reaction occurs between an analyte from the tested sample and the 
corresponding antibody from slide followed by the detection step through various 
methods (e.g., fluorescence-based detection). The slide is further scanned, followed 
by image acquisition, data processing, and analysis. There are several classifica-
tions of this technique, but it could fall into two main categories: direct phase (e.g., 
antibody-, protein-, peptide array) and reverse or indirect phase where sample of 
interest is spotted on a slide and the corresponding antibody is further added.
Among all these variants, the antibody array type is preferred in tumor research 
domain or in biomarkers discovery/quantification due to technique’s high versatil-
ity and reproducibility [46]. The reverse phase array format could also be used for 
biomarker discovery because it is specificity but has the disadvantage of being more 
laborious.
It is worth to emphasize that protein microarray could be customized in terms of 
number and multiplicity of tested analytes one achieving new research and clinical 
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benefits through this technology. Thus, although fundamental research purposes 
prevail when it comes to array platforms, there is also a recent increasing trend in 
clinical research, diagnostics, and even industry applications such as pharmacy or 
food. For instance, recent attempts are made in using array platform for autoim-
mune disease insights. Thus, novel antigen arrays have been developed in order to 
discover new autoantibody targets, providing analysis for hundreds of samples and 
of their reactivity pattern against thousands of antigens simultaneously [47].
Customizing an array in relation to clinical purpose confirms the flexibility of 
these platforms in assisting molecular management of the disease. A customized 
platform was designed in order to monitor severe acute respiratory syndrome 
(SARS) infection by screening hundreds of sera based on the reactivity against 
certain selected proteins from SARS coronavirus. Authors have reported that with 
this customized array, viral infection could be monitored for many months after 
infection [48]. This type of microarray platform has been further updated to a 
serological assay for the specific detection of IgM and IgG antibodies against the 
S1 receptor-binding subunit of the spike protein of emerging human coronavirus 
hCoV-EMC and SARS-CoV as antigens [49].
Protein microarray is a technology in continuous evolution offering multiple 
possibilities in updating other proteomic techniques. Therefore, the development 
of the “microwestern array” is a clear proof how traditional methods like Western 
blot can be linked to novel technology, thus significantly expanding the research 
technological arsenal [50].
Data generated by ELISA and WB require sometimes additional complementary 
proteomic methods to supplement and even support the scientific information. 
Such supportive task is often accomplished by protein microarrays providing 
important evidence on modulation of signaling networks and potential targets (or 
pathways); these factors or networks must first be identified, and array platforms 
allow exactly this development by exploring dozens of targets simultaneously 
within a single sample, providing lots of data which may be further investigated 
using traditional ELISA or WB techniques [51].
6. Luminex xMAP array
An important improvement in the biological assay field was made in the late 
1990s when Luminex xMAP technology was launched. xMAP technology combines 
the principles of ELISA and flow cytometry, but goes beyond the limitations of 
solid-phase reaction kinetics and is suitable for high throughput, multiplex, and 
simultaneous detection of different biomarkers within a very small volume sample. 
Bringing together advanced fluidics, optics, and digital signal processing with 
proprietary microspheres, xMAP technology became one of the fastest growing 
multiplex technologies. Featuring a flexible open-architecture design, xMAP 
technology enables the configuration of various assays, quickly, cost effectively, and 
accurately, useful in clinical and research laboratories [52].
A key component of Luminex xMAP technology is represented by proprietary 
color-code polystyrene microspheres (beads) internally dyed with precise concen-
trations of two or three spectrally distinct fluorochromes. Through precise concen-
trations of these specific dyes, up to 500 distinctly bead sets can be developed, with 
a different spectral signature.
Based on fluorescent reporter signals, high-speed digital-signal processors 
identify each individual microsphere and quantify the result of every bioassay. The 
capability of adding multiple conjugated beads to each sample results in the ability 
to obtain multiple results from each sample [53].
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There are different types of advanced detection platforms (as depicted in Table 1), 
and therefore, various biomarker panels could be analyzed. Accordingly, validation 
of novel biomarkers into multiplex immunoassay panels confers an attractive pros-
pect of simultaneous measurement of multiple analytes in a single patient sample, 
enabling progres-sion monitoring and outcome prediction, even detecting major 
diseases in its earliest stages [54].
Technique Advantages Disadvantages Use
IHC Qualitative
Fast
Easy to detect
Relatively 
inexpensive
Medium specificity
Possible cross reactivity
Routine diagnstic tool
Shows the localisation of antigen
ELISA Quantitative
High sensitivity
Medium specificity
Higher throughput 
than Western blot
Automation 
potential
One protein/analyte at 
a time
False positive results
Labor intensive/time 
consuming/high reagent 
use
Costly setup for 
automation
To quantify a single protein
Confirmation of other screening 
method/validation
Western blot High specificity
High sensitivity
Quantitative
Automation 
potential
One or a small number 
of proteins/analytes at 
a time
Labor intensive/
time consuming for 
the classical method. 
Resolved by the new 
equipments
Qualitative, quantitative, 
especially with the newest 
equipments
Difficult to transfer 
large or hydrophobic 
proteins—false negative 
results
Difficult to automate—
for the classical method. 
Resolved by the new 
equipments
To identify the presence of a 
small number of proteins in the 
same sample (multiplex WB) or 
the presence of protein-protein 
interactions (Far-WB)
Confirmation of other screening 
method/antibodies validation
Bead-based 
array (e.g., 
Luminex® 
technology)
High sensitivity
High throughput 
and speed
Multiplex and 
customizable panels 
of analytes
Open-architecture 
design
Low time, labor, 
and reagent use over 
traditional methods
Versatility
Flexibility
High cost for a specialized 
equipment and a 
validated antibody pair
To quantify (quantitative) 
multiple proteins/panels of 
analytes, in the same well from a 
small amount of sample
Clinical implementation—
available IVD kits
Protein 
microarray
High sensitivity
Medium specificity
Highest throughput
Low time and 
reagent use
High cost for a specialized 
equipment and a 
validated antibody pair
To screen for changes across a 
large number of proteins, in the 
same well from a small amount 
of sample
Immunogenetics
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Some of our studies illustrate significant dysregulation in circulating levels of 
cytokines and angiogenic factors in brain tumors, with over threefold upregula-
tion of IL-6, IL-1 beta, TNF-alpha, and IL-10 and up to twofold upregulation of 
VEGF, FGF-2, IL-8, IL-2, and GM-CSF, with implications in tumor progression and 
aggressiveness, and also involved in disease-associated pain [55, 56].
Currently, Western blot is used to validate/confirm the identified biomarkers, 
and association between the xMAP technology and the Western blot was remarked 
in many studies. Interestingly, one of them emphasized the improvement in diag-
nostic sensitivity of HIV infection in early stages using xMAP technology, increas-
ing the chances of an early accurate diagnosis. Thus, it was observed a superior 
sensitivity of Luminex xMAP compared with Western blot. Out of 87 confirmed 
HIV positive cases, Western blot confirmed 74.7% sensitivity, while Luminex 
xMAP identified 82.8% sensitivity (p < 0.05) [57]. Further advancements will be 
needed for a successful validation of current discoveries, and sustained efforts are 
necessary to expand the translation into clinical applications toward personalized 
medicine [58].
7. Surface plasmon resonance imaging, lab-on-a-chip
Since our goal is not describing surface plasmon resonance imaging (SPRi) 
methodology, we will not insist very much on the description of the technique. We 
will make a brief description of the principle on which SPRi is based.
The first SPR immunoassay was proposed by the team Liedberg, Nylander, 
and Lundström, in 1983 [59]. The SPR immunoassay method is label-free (unlike 
ELISA); no label molecule is required for analyte detection [60]. Moreover, the 
measurement is done in real time, which allows monitoring of the individual steps 
of this technology. SPRi is currently one of the most sensible platforms for studying 
a wide variety of interaction affinities [61, 62], involving nucleic acid sequences 
[63–65], peptides [66], proteins [67, 68], and carbohydrates [69]. It is possible to 
monitor hundreds of molecular interactions simultaneously.
The composition of a biochip consists essentially of a glass prism, coated with 
a thin gold film and a pre-functionalized surface chemistry. The sample to be 
Technique Advantages Disadvantages Use
SPRi Very high sensitivity
Label-free
Real time method
High throughput 
and speed
Multiplex and 
customizable panels 
of analytes
Open-architecture 
design
Low time, labor, 
and reagent use over 
traditional methods
Low time and 
reagent use
Biochip reusable
High cost for a specialized 
equipment
Suitable for liquid 
biological probes
To screen and quantify 
(quantitative) multiple protein 
interactions (and not only)/
panels of analytes, from the 
same sample
Clinical implementation
Table 1. 
Advantages and disadvantages of immunoassay methods presented in this chapter: IHC, ELISA, Western blot, 
bead-based array—Luminex technology, and chip-based array—protein microarray, SPRi.
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analyzed is injected over the biochip, and the detection of a specific molecule can be 
performed by immobilizing a binding partner on the biochip. SPRi makes a nonla-
beling and a real-time detection of biomarkers [70].
The SPRi platform allows the quantitative detection of multiple simultaneous 
multiplex interactions, and many studies are based on this application for screening 
a variety of analytes in different array types. The main advantage of using SPRi in 
immunodiagnostics is the possibility of monitoring the antigen-antibody reaction 
in real-time, estimating kinetics, how quickly it occurs and how durable it is. In 
addition, it does not require any labels.
In comparison to ELISA and Western Blot, SPRi has the advantage of investigat-
ing a large number of different analytes from the same sample (several hundred dif-
ferent spots can be placed on a biochip), and after washing the biochip, it is possible 
to immediately analyze another sample. SPRi takes less time than other methods. 
The disadvantage of SPRi would be that only liquid biological samples (blood, 
urine, cerebrospinal fluid, and cell culture medium) can be analyzed, and it does 
not analyze biological samples from different tissues/tissue lysates. SPRi is very 
effective when there are many samples and many different interactions to analyze, 
but for a small number of samples or to demonstrate only one type of interaction 
between two proteins, for example, WB is more efficient.
As a conclusion regarding the technologies presented in this chapter, we show 
Table 1 with the advantages and disadvantages of each method.
8. Immunoassay methods in immunogenetic disease diagnostic
Indirect immunofluorescence (IIF) for autoantibody analysis is one of the routine 
diagnostic methods. Different tissue sections or human tumor cell lines—HEp-2—
are used as the source of antigen over which the serum of patients with specific 
autoantibodies is applied [71].
The antinuclear antibody (ANA) test is such a standard screening assay. The 
American College of Rheumatology declared HEp-2 IIF as the preferred method 
for ANA screening [72]. The large amount of ANAs can indicate an autoimmune 
disease, including systemic lupus erythematosus, Sjogren’s syndrome, scleroderma, 
rheumatoid arthritis, idiopathic inflammatory myopathy, and others.
One of the immunohistochemistry method applications in autoimmune 
disease diagnosis is the detection of the presence of MHC I and, more recently, of 
MHC II in skeletal muscle of patients with idiopathic inflammatory myopathies 
(IIMs). It is a group of autoimmune systemic diseases, of which the most com-
mon forms are dermatomyositis, polymyositis, and inclusion body myositis. The 
study of muscle biopsy makes the difference in diagnosis between subtypes, but 
also among other types of myopathies and IIMs. In addition to other pathological 
features, the presence of MHC I and MHC II in sarcolemma gives the certainty 
of diagnosis, as long as they are not present in normal muscles [73–76]. Their 
overexpression in IIMs is induced by cytokines, including interferon and tumor 
necrosis factor alpha (TNF alpha) [77]. A study of 120 muscle biopsies from 
patients with different forms of IIMs showed a presence of MHC I in all biopsies 
and MHC II in 93% of them [76].
The MHC I expression appears early and precedes the lymphocyte infiltrate 
[78], persisting in late disease, and it is not attenuated by immunosuppressive treat-
ment [79–81].
MHC II expression on antigen presenting cells activates T-helper cells and initi-
ates an immune response without knowing the mechanism by which MHC II alleles 
mediate susceptibility to a given autoimmune disease [82].
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From our experience in IIM cases where the IHC is not conclusive, a WB veri-
fication or validation is of great help in highlighting MHC I and II bands at their 
specific molecular weight.
From the more recent studies, we mention that the anti-signal recognition 
particle antibodies in the serum of IIM patients have diagnostic and prognostic 
value especially in the forms of immune-mediated necrotizing myopathy [83]. The 
authors draw attention to a mandatory IIF test along with the dot immunoassay 
to avoid false positive results from the latter method in pathologies not associated 
with IIM. The results sometimes depend on the nature of the antigen used in the 
technique and can be denatured.
ELISA is used as a diagnostic tool in autoimmune diseases, for evaluation of 
serum autoantibodies. Antinuclear antibodies (ANAs) directed against a variety of 
nuclear and cytoplasmic antigens are found with a high frequency in many systemic 
autoimmune disorders like systemic lupus erythematosus, scleroderma, Sjogren’s 
syndrome, myositis, etc. ANA-HEp-2 Screen ELISA is an immunoassay method for 
the qualitative combined detection of IgG antibodies against human serum HEp-2 
cells. Each well is coated with Hep-2 cellular lysate. The test detects in a well plate 
total ANAs against double stranded DNA, histone, SS-A (Ro), SS-B (La), Sm, 
snRNP/Sm, Scl-70, PM-Scl, Jo-1, and centromeric antigens.
HEp-2 cells allow the recognition of over 30 nuclear and cytoplasmic patterns that 
are given upwards of 50 different autoantibodies [84, 85]. The specificity of the test 
is closely related to the quality of the antigens used [86]. It is one of the most com-
mon methods of diagnosis in organ-specific autoimmune diseases, such as Grave’s 
disease, primary biliary cirrhosis, insulin-dependent diabetes mellitus or systemic 
autoimmune disorders affecting different organs, such as systemic sclerosis, Sjogren’s 
syndrome, and mixed connective tissue disease rheumatoid arthritis [87, 88].
From recent research studies [89], we want to mention cortactin antibodies 
as new biomarkers in double seronegative myasthenia gravis (myasthenia gravis 
form dSNMG). ELISA tests validated by WB have demonstrated that the presence 
of cortactin autoantibodies is a biomarker to be taken into account, suggesting 
that the disease will be ocular or mild generalized and could be done routinely in 
the future.
Another work on rheumatoid arthritis shows that, apart from the autoantibody 
system that recognizes citrullinated proteins, the identification of another antibody 
system against carbamylated proteins has an important early diagnostic value, pre-
dicting a more severe course of disease [90]. The ELISA method used in this study 
could become routine for serum testing of patients with rheumatoid arthritis.
Western blot. To highlight the importance of WB technique in clinical diag-
nosis, we give some eloquent examples below. The WB method has been used in 
many studies, along with immunoprecipitation, ELISA, and flow cytometry, to 
demonstrate the quantitative or qualitative modification of proteins of interest in 
autoimmune diseases in order to find new biomarkers or therapeutic targets. WB 
has proven to be a good tool for serological tests.
Line-blot immunoassay is a Western blotting method that uses recombinant anti-
gens immobilized on straight lines on a nylon strip. They are incubated with patient 
serum containing autoantibodies. They bind to the antigens present on the strip 
and are viewed colorimetrically. Interpretation of the results is done by comparing 
the color intensity of strips with the color of strips of a positive standard. There are 
some studies that have shown the utility of this method in the detection of auto-
antibodies present in serum but which could not be identified by IIF, for example, 
anti-SS-A/Ro in Sjogren’s syndrome [91, 92].
Haroon et al. have demonstrated using the WB method that there is an interac-
tion between endoplasmic reticulum aminopeptidase 1 (ERAP1) with human 
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leucocyte antigen (HLA)-B *27 in ankylosing spondylitis [93], and that the HLA-
B27 molecules could alter the ERAP1 level. The functional interaction between 
ERAP1-peptide and HLA-B27 could thus be the missing link in the pathogenesis of 
ankylosing spondylitis.
Stagakis et al. studied whether anti-TNF therapy improves insulin resistance in 
rheumatoid arthritis [94]. Western blot was used to analyze the proteins p-Ser312 
IRS-1 and p-AKT from peripheral blood mononuclear cell lysates. It has been 
established that anti-TNF alpha therapy has a positive effect, improving insulin 
sensitivity and reversing the defects in signaling insulin cascade in this disease.
Tsui et al. have conducted a study of the serum levels of noggin (NOG) and 
sclerostin (SOST) in patients with ankylosing spondylitis, more specifically, on the 
immune response to these two molecules [95]. The WB method was used to quan-
tify the relative amounts of NOG/SOST-IgG immune complexes. An increased level 
of NOG/SOST-IgG immune complexes was found in patients with this pathology.
Rizzo et al. [96] showed that the dimeric form of the HLA-G molecule is associ-
ated with the response to methotrexate treatment in patients with early rheumatoid 
arthritis. HLA-G dimeric and monomeric forms have been highlighted by WB. The 
presence of dimeric form in plasma prior to methotrexate therapy could be a 
biomarker for the patient’s response to treatment.
Protein microarray. Antibody microarrays could provide a real-time vision of 
biological processes, such proteomic instrument being used in clinic to analyze 
serum and plasma in several pathologies including autoimmune disorders. One 
of the autoimmune diseases approached through protein array is systemic lupus 
erythematosus (SLE) where SLE clinical heterogeneity and the absence of robust 
biomarkers to evaluate the disease states and differentiate from other autoimmune 
conditions are yet to be resolved [97]. Thus, using an antibody-based leukocyte-
capture microarray, mononuclear cells isolated from peripheral blood of 60 SLE 
patients were processed for obtaining proteomic patterns to distinguish SLE from 
healthy subjects. With this array platform, it was improved the conventional SLE 
diagnostics and disease states elucidation [98]. Moreover, an “in-house” antibody 
microarray comprising 135 human recombinant single-chain fragment variables 
aiming various immune proteins were used to examine systemic sclerosis (SSc) and 
SLE patients. This tailored array identified a significant number of differentially 
expressed proteins that delineate SLE from systemic sclerosis, thus surpassing 
disease classification through conventional clinical parameters, including, ANA, 
anti-DNA, SLEDAI-2 k, C1q, C3, C4, and CRP [99].
Another challenging field for protein array is related to rheumatoid arthritis (RA) 
as it could detect biomarkers specific for arthritis and not for autoimmune diseases 
in general [100]. Some research groups have started to develop different antigen 
arrays for differential diagnosis and even RA molecular classifying. Panels of 
proteins were detected, among these three proteins, namely, WIBG, GABARALP2, 
and ZNF706, were suggested as potential specific markers for RA early stages [101]. 
Hence, protein arrays bring valuable data to immune-disease background allowing 
exploration of numerous samples in parallel and thousands of targets.
Antibodies against ion channels, receptors, synaptic proteins, etc. confirm 
protein microarrays as a future potential tool in routine diagnosis [102]. Whatever 
commercially available or customized platforms, antibody arrays start to emerge in 
clinic by designing omics disease signatures helping the disease management.
The protein microarray was used in a study of pemphigus vulgaris, an autoim-
mune skin disease, to identify the entire set of antibodies, bringing extra data 
about the complex relationship between genetics and disease development [103]. 
The results were correlated with those obtained by the ELISA and proved to be 
compatible. The main targets for autoantibodies are desmoglein-3 and 1, but the 
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study showed that there are autoantibodies that are not directed to desmoglein at a 
significant number of patients.
A study regarding ankylosing spondylitis using the protein microarray, confirmed 
by ELISA, to characterize anti-ankylosing spondylitis autoantibodies, showed that 
anti-protein phosphatase 1A (PPM1A) autoantibodies are present in the serum of 
the patients and that they could serve not only as biomarkers for diagnosis, disease 
severity, and response to anti-TNF therapy, but also as a therapeutic target [104].
Luminex xMAP technology has developed as an alternative to planar microarray 
methods. Bead-based immunoassays are one of them. The determinations by this 
method and by ELISA of anti-thyroid peroxidase and anti-thyroglobulin antibodies 
in autoimmune diseases have been shown to be compatibles [105].
There is a commercially available kit for ANA detection, which is low cost and 
saves time. Antigens corresponding to autoantibodies are linked to polystyrene 
microspheres labeled internally with different amounts of two different fluoro-
chromes, resulting in 100 different color spectra. Each microbead carries an antigen 
specific for a single antibody [106].
Good results were obtained in assessing a number of antinuclear autoantibodies as: 
dsDNA, Sm and Sm/RNP (in systemic lupus erythematosus), SS-A/Ro and SS-B/La 
(in Sjogren’s syndrome), Jo-1 (myositis), ribosome (systemic lupus erythematosus), 
and centromere (systemic sclerosis) [107].
One of the problems with this technology could be the lack of a true quantitative 
calibration due to the difference in affinity of the antibodies for the antigen [108]. 
Some authors argue that it is also necessary to validate the results by other immuno-
assay methods [106], while others claim that the accuracy of the technique is similar 
to that observed by ELISA [109, 110].
There are studies in which the Luminex methodology is used for the analysis of 
serum biomarkers in various autoimmune diseases. Thus, in an article on ankylos-
ing spondylitis, certain cytokines as hepatocyte growth factor (HGF), CXCL8, and 
matrix metalloproteinases (MMP-8 and MMP-9) identified from a large number 
of biomarkers by Luminex could be diagnostic targets, their serum levels being 
increased in this disease [111].
In other chapter regarding ankylosing spondylitis, Luminex bead-based 
technology was used for serum cytokines analysis, and the conclusion was that 
the utilization of TNF alpha inhibitors decreases the number of T cells producing 
proinflammatory cytokines [112].
Mou et al. showed, using Luminex technology in combination with PCR, that in 
ankylosing spondylitis patients from Southern China with HLA-B27 in their serum, 
HLA-B2704 subtype predominates. And the HLA-B2715 subtype may have a disease 
prognostic value, early onset being related to this subtype [113].
Surface plasmon resonance imaging. Despite its great sensitivity, this technology 
is relatively little used to determine the concentration of some analytes. Improving 
signal amplification methods is one of the research goals in this technique.
In some autoimmune diseases, such as rheumatoid arthritis (RA), psoriatic 
arthritis, systemic lupus erythematosus, or Sjogren’s syndrome, autoantibod-
ies attack citrullinated proteins, and the presence of anti-citrullinated proteins, 
antibodies is a standard test in these cases. The use of SPRi for monitoring autoanti-
bodies that bind to different citrullinated targets was first described by Lokate et al. 
SPRi has shown its ability to detect the interaction between citrullinated peptides 
and serum autoantibodies in RA patients in one step [114].
SPRi microarray technique was also used in a more recent research to identify 
autoantibodies against citrullinated protein (ACPA) profiles in patients with early 
onset rheumatoid arthritis. The authors made a comparative study using citrullinated 
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and noncitrullinated peptides [115]. The study showed that SPRi is a suitable meth-
odology for detecting ACPAs in the serum of patients with this pathology.
A subsequent study was also revealed by SPRi, the presence of citrullinated 
B-cell epitopes in fibrinogen [116].
A research team [117] showed the use of SPRi and gold particles to amplify the 
signal for the detection of inflammation biomarker TNF-alpha in serum. Also, the 
use of a specific buffer solution for sample dilution was utilized to reduce the nonspe-
cific binding in real samples. Thus, a low limit of detection, as well as a good repro-
ducibility and the longevity of chips, is a good motivation to use this immunoassay 
method to detect biomarkers that are in low concentrations in biological samples.
Buhl et al. reported in a research paper the use of SPRi technology for the anti-
dsDNA detection in systemic lupus erythematosus [118].
9. Conclusions
Immunoassay methods have many advantages but some limitations too. Their 
importance in identifying different biomarkers for diagnosis or personalized 
therapy is essential. That is why they have diversified so much, in order to be able 
to answer all the challenges. Additionally, these methods and technologies have 
also specialized in an advanced degree, so that they can detect smaller amounts 
of molecules with as high a precision as possible in a shorter time. The antigen-
antibody response gives them great sensitivity. The development of more advanced 
equipment leads to the automation of these methods and to a greater efficiency, 
with applicability in diagnosis and therapeutic monitoring, in discovery of new 
biomarkers and even in pharmacology.
In order to be used for diagnosis in different laboratories, these methods and kits 
should be standardized. The problems to be posed are: the clinical manifestation 
of the disease in different individuals, the source of the antigen, the specificity and 
sensitivity of the autoantibodies for different antigens, the reproducibility of the 
assay, and the precision and the accuracy of the method [91, 119, 120].
Some studies show a good correlation between IIF and ELISA methods [84, 121, 122], 
and others, on the contrary, show different results between these methods [71, 123].
Multiplex technologies are gaining more and more followers in recent years by 
allowing simultaneous analysis of a multitude of analysts, saving time and costs. 
However, there are studies showing that compared to the old methods, some false 
negative or false positive results are obtained [124–128]. Cross reactivities may also 
occur [129].
Assay kits produced by different manufacturers can show variable results also. 
More than this, the methodology used by each laboratory can lead to different 
results, even by using the same kit. International standardization is required. A 
collaboration between an international body and organizations responsible for 
quality of assessment of assays is desirable, so that a collaboration among clinicians, 
diagnostic laboratories, and manufacturers to be established.
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